Thyrocare Technologies experienced a 16% stock surge to ₹1,474 following positive Q2 results and a bonus issue announcement. The company reported 22% revenue growth and an 82% increase in PAT, while expanding its lab presence.
Thyrocare Technologies experienced a 16% stock surge to ₹1,474 following positive Q2 results and a bonus issue announcement. The company reported 22% revenue growth and an 82% increase in PAT, while expanding its lab presence.